Regal Rexnord (RRX) Q1 2026 Earnings Transcript

Regal Rexnord reported solid Q1 results with net sales up 4.3%, organic sales up 1.6%, adjusted EPS of $2.17, and company-wide daily orders up 8.5%, driving backlog up 6.7% sequentially. Management raised full-year sales growth guidance to 4.5% from prior expectations and highlighted strong momentum in AMC, where orders rose 34% and organic sales grew over 12%, though EBITDA margins were pressured by OEM-heavy mix, tariffs, and rare earth costs. The company also named Aamir Paul as incoming CEO by July 1 and lowered its estimated annual unmitigated tariff impact to $127 million from $155 million.

Analysis

RRX is transitioning from a pure cyclical recovery story to a higher-quality secular compounding story, and that matters more than the near-term guide haircut. The key second-order effect is that OEM-heavy growth is simultaneously a top-line accelerant and a margin cap, which means the stock will likely trade on whether investors believe the mix drag is temporary or structural. If management is right that backlog and tariff normalization help margins into the back half, then current skepticism is creating an asymmetric setup into 2H26 and especially 2027.

The market is probably underestimating how much the data-center and cross-sell funnels can offset legacy industrial softness. The real option value is not just ePOD sales, but the installed-base pull-through that comes after the first shipment wave; that creates a multi-year annuity-like aftermarket stream with materially better economics than today’s OEM mix. In other words, 2026 may look modest on margin, but it is laying the base for a 2027-28 step-up if the conversion rate on the funnel remains intact.

The main risk is that the stock is being asked to bridge a lot of moving parts: tariffs, rare-earth timing, and a CEO transition all at once. The near-term catalyst path is cleaner than the risk path because revenue visibility is improving, but margin relief is still conditional on mix reverting and supply costs normalizing. If OEM remains dominant beyond the next two quarters, the market will likely fade the multiple expansion even if orders stay strong.

Consensus seems too focused on the guide being conservative and not enough on the fact that the company is effectively buying growth optionality with muted margin optics. That makes the setup attractive for investors with a 6-12 month horizon, but not for anyone needing a clean quarter-to-quarter EBITDA beat story. I would view pullbacks on any short-term margin disappointment as an opportunity, provided order momentum does not break.

Key Decisions for Investors

• Go long RRX on a 6-12 month horizon on any post-earnings pullback; the setup is better for price-to-sales/mid-cycle multiple re-rating than for immediate EPS beats, with upside if margin mix normalizes in 2H26.
• Pair trade: long RRX / short a more domestically exposed industrial OEM with weaker data-center exposure; RRX has clearer secular growth optionality while the short leg should be more exposed to plain-vanilla industrial deceleration.
• For options traders, buy 3-6 month RRX call spreads rather than outright stock to capture a potential rerating from backlog/order strength while limiting downside if OEM mix keeps margins capped.
• Do not chase after a strong tape; wait for any 3-5% drawdown tied to margin concern or CEO-transition noise, since that is where the market is most likely to misprice the 2027 optionality.
• If RRX fails to show sequential margin improvement over the next two quarters, reduce exposure quickly; the thesis is order-driven, but the multiple depends on proof that the mix drag is transitory.